The Chronic Plaque Psoriasis industry continues to witness robust advancements driven by evolving therapeutic options and rising patient awareness.

Market Size and Overview The chronic plaque psoriasis market is estimated to be valued at USD 24.43 Bn in 2025 and is expected to reach USD 38.47 Bn by 2032, growing at a compound annual growth rate (CAGR) of 6.7% from 2025 to 2032.

Market Segments Chronic Plaque Psoriasis market analysis reveals three core segment categories: Product Type, Distribution Channel, and End User.

• Product Type: Biologics dominate the market share, led by innovations in IL-17 and IL-23 inhibitors such as secukinumab and guselkumab, which demonstrated rapid adoption in 2024 with a 15% year-over-year growth rate. Small molecule therapies, particularly JAK inhibitors, are the fastest-growing sub-segment, supported by clinical trial successes and favorable outcomes in treatment effectiveness.
• Distribution Channel: Hospital pharmacies remain dominant due to direct physician prescriptions. Meanwhile, retail pharmacies are the fastest-growing channel, driven by rising patient preference for convenience and expanded pharmacy services.
• End User: Hospitals lead with the largest industry size, given their capacity to manage complex chronic cases. Specialized dermatology clinics represent the fastest-growing sub-segment, capitalizing on focused treatment protocols and personalized patient management.

‣ Chronic Plaque Psoriasis Market: https://www.coherentmi.com/industry-reports/chronic-plaque-psoriasis-market